|
|
News for Healthier Living
New Insights About Brain Receptor May Pave Way for Next-Gen Mental Health Drugs
 In a discovery that could guide the development of next-generation antidepressants and antipsychotic medications, researchers at the Icahn School of Medicine at Mount Sinai have developed new insights into how a critical brain receptor works at the molecular level and why that matters for mental health treatments.
The study, published in the August 1 online issue of Science Advances [10.1126/sciadv.adu9851], focuses on the 5-HT1A serotonin receptor, a major player in regulating mood and a common target of both traditional antidepressants and newer therapies such as psychedelics. Despite its clinical importance, this receptor has remained poorly understood, with many of its molecular and pharmacological properties largely understudied--until now.
August 4, 2025
August 15 2025August 14 2025August 13 2025August 12 2025August 11 2025August 10 2025August 9 2025August 8 2025August 7 2025August 6 2025August 5 2025August 4 2025August 3 2025August 2 2025
|
|
|
|
|